.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
BLOG
Read on
%201.png)
Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Leveraging Partnerships to Achieve Cell Therapy Success
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Master Cell Banks: Laying the Foundation to Final Product Success
Consider our top 5 FAQs when it comes to MCBs Master cell banks (MCBs) are a critical starting material that lay the foundation for the scale-up and...
Looking Ahead: What Does the Future Have in Store for Nucleic Acid-Based Therapies?
A Q&A with Aaron Larsen Aaron Larsen is the Technical Head for the Nucleic Acids Franchise with Resilience. He began working with nucleic acids back...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
